Literature DB >> 15289816

Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse.

P-W Zhang1, H Ishiguro, T Ohtsuki, J Hess, F Carillo, D Walther, E S Onaivi, T Arinami, G R Uhl.   

Abstract

A number of lines of evidence make the gene that encodes the G-protein-coupled CB1/Cnr1 receptor a strong candidate to harbor variants that might contribute to individual differences in human addiction vulnerability. The CB1/Cnr1 receptor is the major brain site at which cannabinoid marijuana constituents are psychoactive as well as the principal brain receptor for endogenous anandamide ligands. It is densely expressed in brain circuits likely to be important for both the reward and mnemonic processes important for addiction. Altered drug effects in CB1/Cnr1 knockout mice and initial association studies also make variants at the CB1/Cnr1 locus candidates for roles in human vulnerabilities to addictions. However, many features of this gene's structure, regulation and variation remain poorly defined. This poor definition has limited the ability of previous association studies to adequately sample variation at this locus. We now report improved definition of the human CB1/Cnr1 locus and its variants. Novel exons 1-3, splice variant and candidate promoter region sequences add to the richness of the CB1/Cnr1 locus. Candidate promoter region sequences confer reporter gene expression in cells that express CB1/Cnr1. Common polymorphisms reveal patterns of linkage disequilibrium in European- and in African-American individuals. A 5' CB1/Cnr1 "TAG" haplotype displays significant allelic frequency differences between substance abusers and controls in European-American, African-American and Japanese samples. Post-mortem brain samples of heterozygous individuals contain less mRNA transcribed from the TAG alleles than from other CB1/Cnr1 haplotypes. CB1/ Cnr1 genomic variation thus appears to play roles in human addiction vulnerability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289816     DOI: 10.1038/sj.mp.4001560

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  88 in total

1.  Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.

Authors:  Joseph P Schacht; Kent E Hutchison; Francesca M Filbey
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.

Authors:  Jose M de Miguel-Yanes; Alisa K Manning; Peter Shrader; Jarred B McAteer; Anuj Goel; Anders Hamsten; Caroline S Fox; Jose C Florez; Josée Dupuis; James B Meigs
Journal:  Obesity (Silver Spring)       Date:  2011-06-02       Impact factor: 5.002

3.  Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.

Authors:  J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

Review 4.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

5.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

6.  Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence.

Authors:  Aryeh I Herman; Henry R Kranzler; Joseph F Cubells; Joel Gelernter; Jonathan Covault
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-07-05       Impact factor: 3.568

7.  Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.

Authors:  Francesca M Filbey; Joseph P Schacht; Ursula S Myers; Robert S Chavez; Kent E Hutchison
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

8.  Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

Authors:  D Proudnikov; T Kroslak; J C Sipe; M Randesi; D Li; S Hamon; A Ho; J Ott; M J Kreek
Journal:  Pharmacogenomics J       Date:  2009-12-15       Impact factor: 3.550

9.  Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Qing-Rong Liu; Sanika S Chirwa; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption.

Authors:  E S Onaivi; O Carpio; H Ishiguro; N Schanz; G R Uhl; R Benno
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.